Cannabis and Epilepsy Research: Clinical Evidence and Treatment Outcomes

Executive Summary

Cannabis-based treatments for epilepsy represent one of the most rigorously studied medical applications of cannabinoids, yet new research continues to challenge assumptions about efficacy and safety. A September 2026 study raised concerns that some epilepsy patients using cannabis may experience increased seizure frequency, complicating a narrative shaped largely by the 2018 FDA approval of Epidiolex (cannabidiol) for rare childhood epilepsies. The relationship between cannabis and seizure disorders spans decades of patient advocacy, clinical trials, regulatory milestones, and ongoing scientific debate. Approximately 3.4 million Americans live with active epilepsy, and an estimated 30% develop drug-resistant forms that drive families toward alternative therapies including CBD and whole-plant cannabis. This topic sits at the intersection of neurology, federal drug scheduling, state medical marijuana programs, and a global pharmaceutical market for cannabinoid medications projected to exceed $5 billion by 2028. Understanding cannabis and epilepsy research requires examining controlled clinical trials, real-world patient registries, the biochemical mechanisms of cannabinoids in the brain, and the regulatory frameworks that determine which patients can legally access these treatments.

Why This Matters

Epilepsy patients, particularly children with treatment-resistant syndromes, represent the most legally protected medical cannabis population in the United States. The condition's severity and the documented efficacy of pharmaceutical-grade CBD created political consensus that transcended partisan divides on cannabis policy. At least 47 states now permit CBD products for epilepsy, even in jurisdictions that otherwise prohibit medical marijuana, creating a unique legal carve-out that influenced broader cannabis reform.

For families, the stakes are existential. Dravet syndrome and Lennox-Gastaut syndrome—two rare epilepsies affecting children—can produce hundreds of seizures monthly, causing developmental regression, injury risk, and premature death. When Charlotte Figi, a Colorado child with Dravet syndrome, experienced dramatic seizure reduction using a high-CBD cannabis strain in 2013, her story catalyzed a patient migration to Colorado and inspired "Charlotte's Web" laws in conservative states. The Figi family's advocacy directly influenced at least 15 state legislatures between 2014 and 2016.

The pharmaceutical industry invested heavily following Epidiolex's approval. GW Pharmaceuticals (now Jazz Pharmaceuticals) generated $673 million in Epidiolex revenue in 2021 alone. Competitors including Zynerba Pharmaceuticals, Tilray, and Benuvia Therapeutics have pursued cannabinoid epilepsy treatments, while academic medical centers established specialized clinics integrating CBD into standard-of-care protocols. The Cleveland Clinic, NYU Langone, and UCLA now operate dedicated cannabinoid epilepsy programs.

Neurologists face clinical uncertainty. While Epidiolex demonstrated efficacy in controlled trials, real-world outcomes vary widely. Patients using artisanal cannabis products encounter dosing inconsistencies, unknown cannabinoid ratios, and potential drug interactions. The September 2026 study suggesting increased seizures in some cannabis users underscores the need for rigorous patient monitoring and challenges the assumption that "natural" cannabis is universally safer than synthetic pharmaceuticals.

Background and History

The modern era of cannabis epilepsy research began in the 1970s, though historical references to cannabis treating convulsions date to ancient medical texts. The scientific foundation emerged from Israeli chemist Raphael Mechoulam's isolation of THC in 1964 and CBD in 1963, enabling controlled study of individual cannabinoids rather than whole-plant preparations.

Early Clinical Investigations (1973-1990)

In 1973, Brazilian researchers led by J.M. Cunha published preliminary findings that CBD reduced seizure frequency in a small cohort of patients with treatment-resistant epilepsy. The study, involving 15 patients receiving 200-300 mg daily CBD for up to 4.5 months, reported that four patients became seizure-free and three showed significant improvement. Methodological limitations prevented definitive conclusions, but the work established proof-of-concept.

Throughout the 1980s, sporadic case reports and small trials explored CBD's anticonvulsant properties. A 1980 double-blind study at the University of São Paulo administered CBD to eight patients with secondary generalized epilepsy, finding that half experienced reduced seizure frequency. Concurrent animal research demonstrated CBD's ability to suppress chemically induced seizures in rodent models, identifying potential mechanisms involving GABA neurotransmission and voltage-gated sodium channels.

Progress stalled due to cannabis's Schedule I classification under the Controlled Substances Act of 1970 (21 U.S.C. § 812), which restricted research access and pharmaceutical development. Between 1985 and 2000, fewer than a dozen peer-reviewed studies examined cannabinoids for epilepsy, a research drought that left families without evidence-based guidance.

The Charlotte Figi Era (2011-2014)

In 2011, Charlotte Figi's parents in Colorado Springs sought cannabis treatment after exhausting conventional therapies for their daughter's Dravet syndrome. Working with the Stanley Brothers, Colorado cultivators, they developed a high-CBD, low-THC strain later named Charlotte's Web. Charlotte's seizures reportedly decreased from 300 monthly to 2-3 monthly, a transformation documented in Sanjay Gupta's 2013 CNN documentary "Weed."

The media coverage triggered a patient exodus to Colorado, where medical marijuana was legal and CBD products accessible. By 2014, an estimated 250 families had relocated to Colorado seeking similar treatments, a phenomenon journalists termed "medical marijuana refugees." The Stanley Brothers' company, CW Hemp (now Charlotte's Web Inc.), scaled production to meet demand, distributing CBD oil to thousands of patients nationwide.

State legislatures responded rapidly. In 2014, Utah enacted the Charlee's Law (named after another child with epilepsy), permitting CBD possession for patients with intractable epilepsy. Alabama, Florida, Iowa, Kentucky, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Utah, and Wisconsin all passed CBD-specific epilepsy laws between 2014 and 2015. These statutes typically restricted THC content to 0.3% or less and required physician certification of epilepsy diagnosis.

FDA Approval and Pharmaceutical Development (2015-2018)

GW Pharmaceuticals, a British company specializing in cannabinoid medicines, initiated Phase III trials of Epidiolex (highly purified CBD) in 2015. The trials focused on Dravet syndrome and Lennox-Gastaut syndrome, two rare epilepsies affecting approximately 1 in 15,000 children. The company enrolled 516 patients across multiple international sites, administering 10 mg/kg or 20 mg/kg daily CBD alongside existing antiepileptic drugs.

Results published in The New England Journal of Medicine in 2017 showed that CBD reduced convulsive seizure frequency by a median of 39% in Dravet syndrome patients, compared to 13% with placebo. In Lennox-Gastaut syndrome trials, CBD reduced drop seizures by 42% versus 17% with placebo. Adverse effects included somnolence, decreased appetite, diarrhea, and elevated liver enzymes in patients taking valproate concurrently.

On June 25, 2018, the FDA approved Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older, marking the first FDA approval of a drug derived from cannabis. The DEA subsequently rescheduled FDA-approved CBD medications containing less than 0.1% THC to Schedule V under 21 U.S.C. § 811, while botanical CBD remained Schedule I.

The approval created a regulatory paradox: pharmaceutical CBD was legal nationwide, but state-legal cannabis-derived CBD occupied uncertain legal territory. Epidiolex's wholesale acquisition cost launched at approximately $32,500 annually, pricing many families out of access and sustaining demand for unregulated CBD products.

Expansion and Real-World Evidence (2019-2024)

Following FDA approval, academic medical centers established Epidiolex access programs and patient registries. The UAB Epilepsy Center in Alabama, NYU Comprehensive Epilepsy Center, and Children's Hospital Colorado published real-world effectiveness data tracking hundreds of patients. A 2020 meta-analysis in Epilepsia reviewed 11 observational studies encompassing 2,865 patients, finding that 49% experienced at least 50% seizure reduction, while 9% achieved seizure freedom.

In 2020, the FDA expanded Epidiolex's indication to include tuberous sclerosis complex, a genetic disorder causing seizures and developmental disabilities. The approval relied on a trial showing 49% reduction in seizure frequency versus 27% with placebo in 224 patients.

Researchers explored additional cannabinoids and formulations. CBDV (cannabidivarin), a CBD analog, entered Phase II trials for focal epilepsy. Combination therapies pairing CBD with THC or other cannabinoids showed promise in animal models but faced regulatory hurdles for human trials. The National Institutes of Health awarded $3.8 million in epilepsy-focused cannabinoid research grants between 2018 and 2023.

Emerging Concerns (2025-2026)

By 2025, neurologists reported mixed outcomes in clinical practice. While many patients benefited, others experienced no improvement or adverse effects. Drug interactions emerged as a significant concern: CBD inhibits cytochrome P450 enzymes, altering blood levels of clobazam, valproate, and other antiepileptic drugs. A 2025 study in JAMA Neurology found that 23% of patients required dose adjustments of concurrent medications due to CBD interactions.

The September 2026 study suggesting increased seizures in some cannabis users added complexity. While details of the study's methodology and patient population require careful analysis, the findings highlight the need for individualized treatment approaches and rigorous monitoring. Not all epilepsy types respond identically to cannabinoids, and whole-plant cannabis products with varying THC:CBD ratios may produce different effects than pharmaceutical-grade CBD.

Key Players

Regulatory Agencies

The FDA oversees cannabinoid drug approvals and post-market surveillance. The agency's Center for Drug Evaluation and Research approved Epidiolex following standard New Drug Application procedures, requiring proof of safety and efficacy through controlled trials. The FDA continues monitoring adverse event reports through its MedWatch system and has issued warning letters to companies making unapproved epilepsy treatment claims for CBD products.

The DEA controls cannabis scheduling under the Controlled Substances Act. While the agency rescheduled FDA-approved CBD drugs to Schedule V, botanical cannabis and non-FDA-approved CBD remain Schedule I. This creates enforcement ambiguity in states with legal medical cannabis programs. The DEA issues research registrations to institutions studying cannabinoids, though advocates argue the application process remains onerous.

The National Institutes of Health funds cannabinoid epilepsy research through the National Institute of Neurological Disorders and Stroke. NINDS-supported studies examine mechanisms of action, optimal dosing, and long-term safety. The NIH also operates the National Center for Complementary and Integrative Health, which has funded studies on whole-plant cannabis versus isolated cannabinoids.

Pharmaceutical Companies

Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in 2021, gaining control of Epidiolex and a pipeline of cannabinoid therapies. Jazz markets Epidiolex globally and funds ongoing trials exploring additional epilepsy indications. The company reported that approximately 30,000 patients had received Epidiolex prescriptions by 2023.

Zynerba Pharmaceuticals developed Zygel, a CBD transdermal gel for Fragile X syndrome-related seizures. The company completed Phase III trials in 2022 but faced FDA questions about efficacy endpoints, delaying potential approval. Benuvia Therapeutics and Cardiol Therapeutics pursue cannabinoid epilepsy treatments in earlier development stages.

Patient Advocacy Organizations

The Epilepsy Foundation reversed its position on medical cannabis in 2014, calling for increased research access and rescheduling. The organization's advocacy influenced congressional support for the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, though the legislation has not passed. The Foundation operates a patient registry collecting real-world data on cannabinoid use.

RxLeaf, Americans for Safe Access, and Realm of Caring (founded by the Stanley Brothers) provide patient education and advocate for legal protections. Realm of Caring has served over 40,000 patients since 2014, offering subsidized CBD products and connecting families with neurologists experienced in cannabinoid therapy.

Academic Research Centers

The UAB Epilepsy Center in Alabama established one of the first state-sanctioned medical cannabis programs specifically for epilepsy research. Between 2015 and 2023, UAB enrolled over 300 patients in its CBD registry, publishing data showing that 32% of patients experienced at least 50% seizure reduction. NYU Langone's Comprehensive Epilepsy Center, led by Dr. Orrin Devinsky (principal investigator for Epidiolex trials), continues studying cannabinoid mechanisms and treatment optimization.

Legal and Regulatory Framework

Federal law creates a dual system where FDA-approved cannabinoid drugs are legal nationwide, while botanical cannabis remains Schedule I. The Controlled Substances Act (21 U.S.C. § 812) classifies substances into five schedules based on abuse potential and medical utility. Schedule I designation indicates no accepted medical use and high abuse potential, restricting research and prohibiting prescription.

The 2018 Farm Bill (Agriculture Improvement Act of 2018) legalized hemp-derived CBD containing less than 0.3% THC, creating a legal pathway for CBD products marketed as dietary supplements. However, the FDA maintains that CBD cannot be legally added to food or marketed as a dietary supplement without agency approval, creating enforcement uncertainty. The agency has sent warning letters to companies making therapeutic claims but has not systematically removed CBD products from commerce.

State laws vary dramatically. Medical marijuana programs in 38 states and Washington, D.C. include epilepsy as a qualifying condition, allowing patients to access whole-plant cannabis products. CBD-only laws in states like Texas and Georgia permit possession of low-THC CBD oil for epilepsy but prohibit cultivation or in-state production, forcing patients to obtain products from other states or unregulated sources.

Insurance coverage remains limited. While some insurers cover Epidiolex for FDA-approved indications, prior authorization requirements and high copays create access barriers. A 2023 survey found that 41% of Epidiolex prescriptions faced insurance denials, with annual out-of-pocket costs averaging $6,800 for covered patients. State medical marijuana programs do not qualify for insurance reimbursement due to federal prohibition.

State-by-State Breakdown

Alabama

Alabama enacted Carly's Law in 2014, establishing a CBD research program at UAB for epilepsy patients. The program allows patients with debilitating epilepsy to access CBD oil containing no more than 3% THC. In 2021, Alabama passed the Darren Wesley 'Ato' Hall Compassion Act, creating a broader medical cannabis program that includes epilepsy as a qualifying condition. Dispensaries began operations in 2024, though the program limits THC content to 20% for flower products.

California

California's Compassionate Use Act of 1996 (Proposition 215) established the nation's first medical marijuana program, listing epilepsy among qualifying conditions. The state imposes no possession limits for patients with physician recommendations. Adult-use legalization in 2016 (Proposition 64) created a dual market where epilepsy patients can access products through medical or recreational channels. California does not restrict cannabinoid ratios, allowing patients to obtain high-THC, high-CBD, or balanced formulations.

Colorado

Colorado's Amendment 20 (2000) established medical marijuana access for patients with debilitating conditions, later expanded to include epilepsy. The state became the epicenter of CBD epilepsy treatment following Charlotte Figi's story. Colorado law permits patients to possess up to 2 ounces of cannabis and cultivate six plants (three flowering). The state's Marijuana Enforcement Division regulates product testing, requiring cannabinoid potency and contaminant screening. Colorado does not restrict CBD:THC ratios for medical patients.

Florida

Florida passed the Compassionate Medical Cannabis Act in 2014, permitting low-THC cannabis (0.8% THC or less, 10% CBD or more) for epilepsy patients. Amendment 2 (2016) expanded the program to include full-strength medical marijuana for epilepsy and other qualifying conditions. Florida law allows patients to possess up to a 70-day supply as determined by their physician, with no specific weight limit. The state licenses vertically integrated operators who cultivate, process, and dispense products.

New York

New York's Compassionate Care Act (2014) established a medical marijuana program including epilepsy as a qualifying condition. The program initially prohibited smokable flower, restricting patients to oils, tinctures, and vaporizable products. In 2021, New York legalized adult-use cannabis and expanded medical access, removing the smoking ban. Epilepsy patients can possess up to a 60-day supply as determined by their certifying practitioner. The state's Office of Cannabis Management oversees product testing and dispensary licensing.

Texas

Texas enacted the Compassionate Use Act in 2015, creating one of the nation's most restrictive medical cannabis programs. The law initially limited access to patients with intractable epilepsy and capped THC content at 0.5%. Subsequent amendments expanded qualifying conditions and raised the THC limit to 1% (as of 2021). Patients can possess only products from state-licensed dispensaries, and the program prohibits smokable forms. Texas does not permit in-state cultivation by patients.

Market and Business Implications

The epilepsy indication drove early medical cannabis market development and continues influencing product formulation strategies. Dispensaries in medical marijuana states typically stock high-CBD, low-THC products marketed specifically for epilepsy, often using strain names like Charlotte's Web, Harlequin, or ACDC. These products command premium pricing due to perceived medical legitimacy, with CBD-dominant tinctures retailing for $60-$120 per 30 mL bottle.

Multi-state operators including Curaleaf, Trulieve, and Cresco Labs have developed medical-focused brands targeting epilepsy patients. Curaleaf's "Select Squeeze" line includes a 20:1 CBD:THC formulation explicitly marketed for seizure disorders. These products undergo additional testing and quality control to appeal to medically oriented consumers and caregivers seeking pharmaceutical-grade consistency.

The hemp-derived CBD market, legalized by the 2018 Farm Bill, exploded to an estimated $4.6 billion in 2021 before contracting due to regulatory uncertainty and market saturation. Epilepsy remains a primary use case cited by CBD consumers, though the FDA prohibits companies from making therapeutic claims without drug approval. Major retailers including CVS, Walgreens, and Kroger stock CBD products but restrict labeling to avoid FDA enforcement.

Pharmaceutical-grade cannabinoid medications represent a distinct market segment. Jazz Pharmaceuticals' Epidiolex generated $838 million in 2023 revenue, with growth driven by label expansions and international approvals. The company faces potential competition from generic CBD formulations once patents expire, though regulatory exclusivity and physician familiarity may sustain market share. Analysts project the global cannabinoid epilepsy medication market will reach $5.2 billion by 2028.

Investment in cannabinoid epilepsy research continues despite broader cannabis industry contraction. Venture capital firms including Poseidon Asset Management and Tuatara Capital have funded preclinical research on novel cannabinoids including CBDV, THCV, and CBC for seizure disorders. Academic-industry partnerships, such as the collaboration between NYU Langone and Zynerba Pharmaceuticals, leverage institutional research infrastructure to advance clinical development.

What Experts Say

Dr. Orrin Devinsky, director of the NYU Langone Comprehensive Epilepsy Center and principal investigator for the Epidiolex clinical trials, has emphasized the importance of pharmaceutical-grade cannabinoid products for epilepsy treatment. According to published interviews, Devinsky noted that while Epidiolex demonstrated clear efficacy in controlled trials, real-world outcomes depend heavily on proper dosing, drug interaction management, and patient selection. He has cautioned against assuming that artisanal cannabis products will produce identical results to FDA-approved formulations.

The American Epilepsy Society published a position statement in 2021 supporting continued research into cannabinoid treatments while emphasizing that patients should work with neurologists experienced in cannabinoid therapy rather than self-medicating. The organization highlighted concerns about product quality variability, unknown long-term effects, and potential for drug interactions with standard antiepileptic medications.

Dr. Elizabeth Thiele, director of the Pediatric Epilepsy Program at Massachusetts General Hospital and an Epidiolex trial investigator, has described CBD as a valuable addition to the therapeutic arsenal for treatment-resistant epilepsy, according to medical conference presentations. She noted that approximately 30-40% of patients in clinical practice experience meaningful seizure reduction, but emphasized that CBD is not a cure and works best as part of a comprehensive treatment plan including other antiepileptic drugs, dietary interventions, and in some cases surgical options.

Patient advocates including Paige Figi, Charlotte Figi's mother, have argued that families should have legal access to whole-plant cannabis products in addition to pharmaceutical formulations. In public testimony before state legislatures, Figi emphasized that Charlotte's initial improvement came from artisanal cannabis oil, not pharmaceutical CBD, and that some patients respond better to products containing minor cannabinoids and terpenes absent from isolated CBD preparations.

Researchers studying the September 2026 findings on potential seizure increases in some cannabis users have called for careful patient phenotyping to identify which epilepsy types and patient characteristics predict positive versus negative responses. According to emerging commentary in neurology journals, factors including epilepsy syndrome, concurrent medications, cannabinoid ratios, and dosing regimens likely influence outcomes, necessitating individualized treatment approaches rather than one-size-fits-all protocols.

What's Next

The DEA's ongoing evaluation of cannabis rescheduling could significantly impact epilepsy research and patient access. In August 2024, the DEA published a Notice of Proposed Rulemaking to move cannabis from Schedule I to Schedule III, a change that would acknowledge medical utility while maintaining federal control. If finalized, Schedule III classification would ease research restrictions, potentially accelerating clinical trials of whole-plant cannabis formulations for epilepsy. Administrative Law Judge hearings on the proposal are scheduled for early 2027, with a final rule expected by late 2027 or early 2028.

Clinical trials continue expanding the evidence base. A Phase III trial of CBDV for focal epilepsy, sponsored by GW Pharmaceuticals prior to the Jazz acquisition, completed enrollment in 2023 with results expected in 2027. Researchers at the University of Sydney are conducting trials of cannabinoid combinations (CBD plus CBDV) to determine whether multiple cannabinoids produce synergistic effects. The NIH has allocated $12 million for cannabinoid epilepsy research in fiscal year 2027, funding studies on mechanisms of action, biomarkers predicting treatment response, and long-term safety in pediatric populations.

State legislatures continue refining medical cannabis laws. Bills pending in Georgia and North Carolina would expand existing CBD-only programs to permit higher THC content and in-state cultivation. Texas lawmakers have introduced legislation to raise the THC cap from 1% to 5% and add qualifying conditions, though passage remains uncertain given the state's conservative political climate. At least eight states are considering epilepsy-specific provisions in 2027 legislative sessions.

Insurance coverage may expand as long-term safety data accumulates. Several state legislatures have introduced bills requiring insurers to cover FDA-approved cannabinoid medications without prior authorization for patients meeting clinical criteria. The Centers for Medicare & Medicaid Services issued guidance in 2025 clarifying that state Medicaid programs must cover Epidiolex for FDA-approved indications, potentially improving access for low-income epilepsy patients.

The pharmaceutical pipeline includes novel delivery methods and formulations. Zynerba's transdermal CBD gel, if approved, would offer an alternative for patients unable to tolerate oral medications. Researchers are exploring cannabinoid prodrugs designed to improve brain penetration and reduce drug interactions. At least six cannabinoid epilepsy treatments are in Phase II or Phase III development as of 2026.

Patient registries will provide crucial real-world evidence. The Epilepsy Foundation's registry, UAB's ongoing data collection, and international collaborations through the International League Against Epilepsy are tracking thousands of patients using cannabinoid treatments. These datasets will help identify optimal dosing strategies, predict which patients will benefit, and detect rare adverse effects not apparent in controlled trials. Analysis of registry data comparing pharmaceutical CBD to artisanal cannabis products may clarify whether whole-plant formulations offer advantages for specific patient populations.

Further Reading

• FDA Epidiolex Approval Letter and Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
• Controlled Substances Act, 21 U.S.C. § 812 (drug scheduling framework): https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• DEA Diversion Control Division CBD Rescheduling Notice: https://www.deadiversion.usdoj.gov/schedules/
• Epilepsy Foundation Position Statement on Medical Cannabis: https://www.epilepsy.com/advocacy/position-statements
• National Institutes of Health Cannabinoid Research Funding Database: https://reporter.nih.gov/
• Agriculture Improvement Act of 2018 (Farm Bill) Full Text: https://www.congress.gov/bill/115th-congress/house-bill/2
• American Epilepsy Society Clinical Guidelines for Cannabinoid Use: https://www.aesnet.org/
• Jazz Pharmaceuticals Epidiolex Clinical Trial Results: https://www.nejm.org/doi/full/10.1056/NEJMoa1611618
• UAB Epilepsy Center CBD Research Program Data: https://www.uab.edu/medicine/epilepsy/
• State Medical Marijuana Laws Database (National Conference of State Legislatures): https://www.ncsl.org/health/state-medical-cannabis-laws